Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis.
J Antimicrob Chemother. 2011 Oct 25;
Authors: Cataldo MA, Tacconelli E, Grilli E, Pea F,…

[Read more →]

A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection.
J Antimicrob Chemother. 2011 Sep 21;
Authors: Garey…

[Read more →]

Empirical management of community-acquired pneumonia: impact of concurrent A/H1N1 influenza pandemic on guideline implementation.
J Antimicrob Chemother. 2011 Sep 15;
Authors: Cortoos PJ, Gilissen C, Mol PG, Van den Bossche F,…

[Read more →]

A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
…

[Read more →]

Impact of antimicrobial stewardship programme changes on unnecessary double anaerobic coverage therapy.
J Antimicrob Chemother. 2011 Jul 29;
Authors: Rattanaumpawan P, Morales KH, Binkley S, Synnestvedt M, Weiner MG, Gasink LB…

[Read more →]

Is methicillin-resistant Staphylococcus aureus replacing methicillin-susceptible S. aureus?
J Antimicrob Chemother. 2011 Jul 7;
Authors: Mostofsky E, Lipsitch M, Regev-Yochay G
Despite extensive research on the emergen…

[Read more →]

Efficacy and safety of tigecycline: a systematic review and meta-analysis.
J Antimicrob Chemother. 2011 Jun 18;
Authors: Yahav D, Lador A, Paul M, Leibovici L
Background Tigecycline is a novel glycylcycline that exhibi…

[Read more →]

Changing epidemiology of central venous catheter-related bloodstream infections: increasing prevalence of Gram-negative pathogens.
J Antimicrob Chemother. 2011 Jun 10;
Authors: Marcos M, Soriano A, Iñurrieta A, Martínez JA, …

[Read more →]

Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.
J Antimicrob Chemother. 2011 May 30;
Authors: Neoh CF, Liew D, Slavin M, Marriott D, Chen SC, Morrissey O, Stewart K, K…

[Read more →]

Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia.
J Antimicrob Chemother. 2011 May 17;
Authors: Grenier C, Pépin J, Nault V, Howson J, Fournier X, Poiri…

[Read more →]

Hepatic safety of antibiotics used in primary care.
J Antimicrob Chemother. 2011 May 17;
Authors: Andrade RJ, Tulkens PM
Antibiotics used by general practitioners frequently appear in adverse-event reports of drug-indu…

[Read more →]

Changing needs of community-acquired bacterial pneumonia: experience with ceftaroline fosamil. Preface.
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii1
Authors: Johnson AP, Leibovici L

PMID: 21548186 [PubMed …

[Read more →]

Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus.
J Antimicrob Chemother. 2011 May;66 Suppl 4:iv17-iv21
Authors: Gould IM
Current concerns about multiresistance and a d…

[Read more →]

Linezolid: safety and efficacy in special populations.
J Antimicrob Chemother. 2011 May;66 Suppl 4:iv3-iv6
Authors: Gould FK
Linezolid has been in general use in the UK since 2000. Although toxicity, particularly haema…

[Read more →]

Ceftaroline fosamil: a new broad-spectrum cephalosporin.
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii11-iii18
Authors: Laudano JB
Ceftaroline fosamil, the prodrug of the active metabolite, ceftaroline, is a new, bro…

[Read more →]